NEW YORK, Nov. 12, 2020 /PRNewswire/ -- Bridge Medicines, a pioneering drug discovery company focused on advancing promising early technologies from concept to clinic, announced today the additional funding of $10 million to advance its current pipeline of products as well as expand with additional in-licensed technologies.
VPI Pharm Generic Ethacrynate sodium Receives Approval In Us
Par Pharmaceutical today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for ethacrynate sodium for injection USP, equivalent to ethacrynic acid 50 mg. Ethacrynate sodium is the generic version of Aton Pharma's Sodium Edecrin® and is used in the treatment of edema. Par's ethacrynate sodium for injection USP, 50 mg is the first and only generic available.